ReviewRheumatology international2026
International travel considerations for patients with systemic autoimmune inflammatory diseases in the era of novel immunosuppressive therapies.
Review in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
International travel, especially to areas with higher risk of infection, poses unique risks for infectious and non-infectious issues in patients with history of systemic autoimmune inflammatory diseases. We searched Medline, Scopus, and relevant rheumatology and other professional society guidelines for management of vaccinations and travel medications for immunocompromised travelers. The immune status of travelers with a history of systemic autoimmune inflammatory disease may have an impact on the safety and efficacy of vaccines, especially live-attenuated vaccines. For individuals on immunosuppressive medications, live vaccines are generally contraindicated. However, if safe intervals off immunosuppression are possible, live vaccines may be feasible. Chemoprophylaxis for malaria or acute mountain sickness may be indicated based on travel itinerary. Safe international travel is possible for patients with history of systemic autoimmune inflammatory diseases, including for those receiving immunosuppressive therapy, but may warrant coordination between a patient's rheumatologist and a travel medicine provider.
Indexed as
Identifiers
42377583What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.